Endocrine and multiple sclerosis outcomes in patients with autoimmune thyroid events in the alemtuzumab CARE-MS studies

BACKGROUND: Alemtuzumab is an effective therapy for relapsing multiple sclerosis. Autoimmune thyroid events are a common adverse event. OBJECTIVE: Describe endocrine and multiple sclerosis outcomes over 6 years for alemtuzumab-treated relapsing multiple sclerosis patients in the phase 3 CARE-MS I, I...

Descripción completa

Detalles Bibliográficos
Autores principales: Dayan, Colin M., Lecumberri, Beatriz, Muller, Ilaria, Ganesananthan, Sashiananthan, Hunter, Samuel F., Selmaj, Krzysztof W., Hartung, Hans-Peter, Havrdova, Eva K., LaGanke, Christopher C., Ziemssen, Tjalf, Van Wijmeersch, Bart, Meuth, Sven G., Margolin, David H., Poole, Elizabeth M., Baker, Darren P., Senior, Peter A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2023
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9817015/
https://www.ncbi.nlm.nih.gov/pubmed/36619856
http://dx.doi.org/10.1177/20552173221142741

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9817015/
https://www.ncbi.nlm.nih.gov/pubmed/36619856
http://dx.doi.org/10.1177/20552173221142741

Ejemplares similares